{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:09:15Z","timestamp":1788815355500,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.nmd.2026.107376","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:17:35Z","timestamp":1785424655000},"page":"107376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Genetic susceptibility to thrombotic microangiopathy in a 10-month-old patient with SMA type 1: a caveat for gene therapy eligibility"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6358-5937","authenticated-orcid":false,"given":"Rossella","family":"D'Alessandro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Som\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Vacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Salvalaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Guarnone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Cavallina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Rolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Montin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia","family":"Peruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Barberis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Sbaiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Deaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca","family":"Fagioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana Enrica","family":"Mongini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica Silvia","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2026.107376_bib0001","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2026.107376_bib0002","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.nmd.2021.08.009","article-title":"Spinal muscular atrophy: from rags to riches","volume":"31","author":"Mercuri","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2026.107376_bib0003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejpn.2024.06.001","article-title":"2024 update: European consensus statement on gene therapy for spinal muscular atrophy","volume":"51","author":"Kirschner","year":"2024","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.nmd.2026.107376_bib0004","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2026.107376_bib0005","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2026.107376_bib0006","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2026.107376_bib0007","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1056\/NEJMoa2410120","article-title":"Risdiplam in presymptomatic spinal muscular atrophy","volume":"393","author":"Finkel","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2026.107376_bib0008","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.nmd.2026.107376_bib0009","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00415-025-13314-7","article-title":"Advancing personalized spinal muscular atrophy care: matching the right biomarker to the right patient at the right time","volume":"272","author":"Corti","year":"2025","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2026.107376_bib0010","article-title":"Commissioner O of the. FDA approves gene therapy for treatment of spinal muscular atrophy","year":"2025","journal-title":"FDA"},{"key":"10.1016\/j.nmd.2026.107376_bib0011","unstructured":"Itvisma | European Medicines Agency (EMA) 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/itvisma (Accessed July 22, 2026)."},{"key":"10.1016\/j.nmd.2026.107376_bib0012","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41591-025-04119-2","article-title":"Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial","volume":"32","author":"Kwon","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.nmd.2026.107376_bib0013","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41591-025-04103-w","article-title":"Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial","volume":"32","author":"Proud","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.nmd.2026.107376_bib0014","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41434-025-00545-6","article-title":"Thrombotic microangiopathy following gene therapy for 5q-spinal muscular atrophy","volume":"32","author":"Camelo","year":"2025","journal-title":"Gene Ther"},{"key":"10.1016\/j.nmd.2026.107376_bib0015","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1055\/s-0034-1376153","article-title":"Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches","volume":"40","author":"Riedl","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.nmd.2026.107376_bib0016","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s00467-022-05451-2","article-title":"Systematic review of atypical hemolytic uremic syndrome biomarkers","volume":"37","author":"Raina","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nmd.2026.107376_bib0017","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2026.107376_bib0018","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/ph17030394","article-title":"Real-world safety data of the orphan drug onasemnogene Abeparvovec (Zolgensma\u00ae) for the SMA rare disease: a pharmacovigilance study based on the EMA adverse event Reporting System","volume":"17","author":"Ruggiero","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.nmd.2026.107376_bib0019","article-title":"Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study","volume":"47","author":"Wei\u00df","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.nmd.2026.107376_bib0020","article-title":"Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom. The Lancet Regional Health","volume":"37","author":"Gowda","year":"2024","journal-title":"Europe"},{"key":"10.1016\/j.nmd.2026.107376_bib0021","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1055\/a-2413-4345","article-title":"Emerging thrombotic disorders associated with virus-based innovative therapies: from VITT to AAV gene therapy-related thrombotic microangiopathy","volume":"125","author":"Benemei","year":"2025","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.nmd.2026.107376_bib0022","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.nmd.2026.107376_bib26","first-page":"133","volume":"15","author":"Levart","year":"2025","journal-title":"Eculizumab for Thrombotic Microangiopathy Induced by Onasemnogene Abeparvovec in Spinal Muscular Atrophy. Case Rep Nephrol Dial"},{"key":"10.1016\/j.nmd.2026.107376_bib0023","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.nmd.2026.107376_bib0024","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.ekir.2024.04.024","article-title":"Thrombotic microangiopathy as an emerging complication of viral vector-based gene therapy","volume":"9","author":"Schwotzer","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nmd.2026.107376_bib0025","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri ZL","year":"2015","journal-title":"Blood"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896626010448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896626010448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:45:11Z","timestamp":1788813911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896626010448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"alternative-id":["S0960896626010448"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2026.107376","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic susceptibility to thrombotic microangiopathy in a 10-month-old patient with SMA type 1: a caveat for gene therapy eligibility","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2026.107376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107376"}}